SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001564590-21-018847
Filing Date
2021-04-14
Accepted
2021-04-14 17:23:04
Documents
6
Period of Report
2021-06-08

Document Format Files

Seq Description Document Type Size
1 DEF 14A aldx-def14a_20210608.htm DEF 14A 759471
2 GRAPHIC gzgt0cz5nbig000003.jpg GRAPHIC 645
3 GRAPHIC gzgt0cz5nbig000005.jpg GRAPHIC 34646
4 GRAPHIC gzgt0cz5nbig000004.jpg GRAPHIC 44350
5 GRAPHIC gzgt0cz5nbig000001.jpg GRAPHIC 11887
6 GRAPHIC gzgt0cz5nbig000002.jpg GRAPHIC 631
  Complete submission text file 0001564590-21-018847.txt   888370
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36332 | Film No.: 21826494
SIC: 2834 Pharmaceutical Preparations